Deriving Neural Stem Cells from Embryonic Sources
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and efficient way to produce a homogeneous population of neural stem cells with unlimited self-renewal capability derived from embryonic stem cells for treating neural conditions and disorders.
Innovation Solution
A method involving culturing embryonic stem cells as spheres in media containing epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and leukemia inhibitory factor (LIF) to derive neural stem cells, followed by specific differentiation protocols to induce mid-brain dopaminergic lineage and TH-expressing neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If embryonic stem cells are cultured using conventional methods, then cell proliferation occurs, but the population lacks homogeneity and limited self-renewal capability
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions including specific growth factors (bFGF, EGF, LIF), serum-free media composition, and oxygen tension (2-5% O2) to derive neural stem cells from embryonic stem cells that exhibit both homogeneity and unlimited self-renewal capability. The controlled differentiation protocol further refines cell population uniformity while maintaining functional capacity.
2Productivity
If embryonic stem cells are induced to differentiate into neural cells, then neural cell types are produced, but the population becomes heterogeneous
Solution Approach 1:
The patent applies preliminary action by first establishing a homogeneous neural stem cell population through controlled differentiation from embryonic stem cells before inducing further specialization. This preliminary step ensures that subsequent differentiation into specific neural subtypes (dopaminergic neurons, astrocytes, oligodendrocytes) occurs from a uniform starting population, maintaining overall population homogeneity while achieving productive differentiation.
3Adaptability or versatility
If adult stem cells are used for neural therapy, then limited differentiation into neural cell types occurs, but self-renewal capability is restricted
Solution Approach 1:
The patent applies universality by using embryonic stem cells as a universal source that can differentiate into all three major neural cell types (neurons, astrocytes, oligodendrocytes) while maintaining unlimited self-renewal capability. This overcomes the limitation of adult stem cells which are restricted to specific lineages and have finite self-renewal potential, providing a single cell source with both broad adaptability and sustained duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach yields a stable, homogeneous population of neural stem cells with unlimited self-renewal capacity, enabling effective treatment of neural disorders and conditions, such as stroke damage and dopaminergic dysfunction, by providing functional neural cells for grafting and drug screening.
Implementation Method 1
culturing embryonic stem cells as spheres in media containing epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and leukemia inhibitory factor (LIF)
Data Source
AI summary
Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease.